Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

May 28, 2024

https://www.globenewswire.com/news-release/2024/05/28/2889050/0/en/Aprea-Therapeutics-Announces-that-Safety-Review-Committee-SRC-Endorses-Dosing-of-Patients-with-ATRN-119-at-800-mg-Once-Daily-in-Ongoing-ABOYA-119-Clinical-Trial.html

ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential

On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.